Ergebnisse der Anturan-Reinfarkt-Studie

• LITERATUR

• 1 Andersen M. P., Bechsgaard P., Frederik-se J.. et al. Effect of alprenolol on mortality among patients with definitive or suspected myocardial infarction. Lancet 1979; 2: 865-868
• 2 Aspirin Myocardial Infarction Study Res. Group. Aspirin-Studie bei Patienten nach Myokardinfarkt. J. Amer. med. Ass. 1980; 243: 661
• 3 Elwood P. C, Cochrane A. L., Burr M. L., Sweetnam P. M., Williams G., Wesby E., Hughes S. J., Renton R.. A randomized controlled trial of acetylic salicylic acid in the secondary prevention of mortality from myocardial infarction. Brit. med. J. I: 1974; 436-440
• 4 Elwood P. C, Sweetnam P. M.. Aspirin and secondary mortality after myocardial infarction. Lancet 1979; II: 1313
• 5 Rentrop P., Blanke H., Karsch K. R., Kaiser H., Kostering H., Leitz K.. Selective intracoronary thrombolysis in acute myocar-dial infarction and unstable angina pectoris. Circulation 1981; 63: 307
• 6 Temple R., Pledger G. W.. The FDA's critique of the anturane reinfarction trial. New Engl. J. Med. 1980; 303: 1488-1492
• 7 The Anturane Reinfarction Trial Res. Group. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New Engl. J. Med. 1978; 298: 333-334
• 8 The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. New Engl. J. Med. 1980; 302: 250-256
• 9 The Persantine - Aspirine Reinfarction Study (Paris) Research Group. Circulation. 1980; 62: 85-87 (suppl. V)